| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C34H51N3O3S |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Thiomyristoyl is a potent, specific inhibitor of SIRT2, with an IC50 of 28 nM. It is supplied as a white to off-white solid (C34H51N3O3S, MW 581.85) at 98.23% purity.
Physical & Chemical Properties
| CAS Number | 1429749-41-6 |
|---|---|
| Molecular Formula | C34H51N3O3S |
| Molecular Weight | 581.85 g/mol |
| Purity | 98.23% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | O=C(OCC1=CC=CC=C1)N[C@H](C(NC2=CC=CC=C2)=O)CCCCNC(CCCCCCCCCCCCC)=S |
| Target | SIRT2, SIRT1 |
| Signaling Pathway | Cell Cycle/DNA Damage; Epigenetics |
| Solubility | In Vitro: DMSO: ≥ 32 mg/mL (55.00 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) Ethanol: 15.29 mg/mL (26.28 mM; Requires sonication) * "≥" means soluble, but saturation unknown. |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 2 years; -20°C, 1 year. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target[1]
|
SIRT2 28 nM (IC50) |
SIRT1 98 μM (IC50) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | ≥ 32 mg/mL (55.00 mM) | use freshly opened DMSO (absorbed moisture lowers solubility) |
| Ethanol | 15.29 mg/mL (26.28 mM) | requires sonication |
Aliquot the stock solution and store it at -80°C (up to 2 years) or -20°C (up to 1 year); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.5 mg/mL (4.30 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.5 mg/mL (4.30 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
Thiomyristoyl (TM) is a potent, SIRT2-specific inhibitor that has broad anticancer activity but little effect on non-cancerous cells. Inhibiting SIRT2 promotes c-Myc ubiquitination and degradation, which suggests that TM has therapeutic potential against certain c-Myc-driven cancers. TM can inhibit SIRT2 with an IC50 of 28 nM, inhibits SIRT1 with an IC50 of 98 μM, but shows no inhibition of SIRT3 even at 200 μM. Three human breast cancer cell lines (MCF-7, MDA-MB-468, and MDA-MB-231) are inhibited by TM[1].
In Vivo
Tumor growth is inhibited by TM in mouse models of breast cancer. No significant toxicity and no significant weight loss are seen in TM-treated mice. S5H, acetyl-a-tubulin levels are moderately but statistically significantly higher in tumors from TM-treated mice than in those from vehicle-treated mice, suggesting that TM indeed inhibits SIRT2 in vivo[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Cell Assay[1]
Seed 3,000–4,000 cells per well into 96-well plates. After 24 hr, add test compounds (Thiomyristoyl) to the cells at final concentrations from 1 to 50 μM. Incubate the cells for 72 hr, then measure cell viability with the CellTiter-Blue viability assay. Normalize relative cell viability in the presence of test compounds to vehicle-treated controls after background subtraction. Determine IC50 values with GraphPad Prism software. Achieve knockdown of SIRT1-7 in various cell lines by lentiviral infection[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib. Acta Pharmacol Sin 2022 Feb;43(2):457-469. PMID: 33850273
Isobavachalcone, a natural sirtuin 2 inhibitor, exhibits anti-triple-negative breast cancer efficacy in vitro and in vivo. Phytother Res 2024 Apr;38(4):1815-1829. PMID: 38349045
Thiomyristoyl promotes type 2 diabetic wound healing and inhibits scarring via the PPARγ/Sirt3/SOD2 axis. Free Radic Biol Med 2026 Jun 8:254:31-45. PMID: 42264197
LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations. Mol Cancer Ther 2026 Jul 15:10.1158/1535-7163.MCT-26-0182. PMID: 42456172
Thiomyristoyl ameliorates colitis by blocking the differentiation of Th17 cells and inhibiting SIRT2-induced metabolic reprogramming. Int Immunopharmacol 2021 Jan;90:107212. PMID: 33310666
The SIRT2/cMYC Pathway Inhibits Peroxidation-Related Apoptosis In Cholangiocarcinoma Through Metabolic Reprogramming. Neoplasia 2019 May;21(5):429-441. PMID: 30933885
SIRT2 promotes cell proliferation and migration through mediating ERK1/2 activation and lactosylceramide accumulation in prostate cancer. Prostate 2023 Jan;83(1):71-81. PMID: 36082450
